Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Equity Average (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Equity Average for 4 consecutive years, with $193.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 7.55% to $193.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $193.1 million, a 7.55% decrease, with the full-year FY2024 number at $173.1 million, down 29.0% from a year prior.
  • Equity Average was $193.1 million for Q3 2025 at Century Therapeutics, down from $225.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $372.3 million in Q2 2022 to a low of $178.5 million in Q4 2024.
  • A 4-year average of $243.5 million and a median of $217.0 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 37.47% in 2024, then grew 12.59% in 2025.
  • Century Therapeutics' Equity Average stood at $316.5 million in 2022, then tumbled by 36.17% to $202.0 million in 2023, then dropped by 11.62% to $178.5 million in 2024, then increased by 8.18% to $193.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Equity Average are $193.1 million (Q3 2025), $225.2 million (Q2 2025), and $200.9 million (Q1 2025).